PubMed:32352535 / 2316-2582
Annnotations
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T68 | 0-14 | UBERON:0004535 | denotes | Cardiovascular |
| T69 | 69-79 | DG_28 | denotes | remdesivir |
| T70 | 81-92 | DG_10 | denotes | chloroquine |
| T71 | 81-92 | CHEBI:3638 | denotes | chloroquine |
| T72 | 81-92 | CHEBI:3638 | denotes | chloroquine |
| T73 | 94-112 | DG_20 | denotes | hydroxychloroquine |
| T74 | 94-112 | CHEBI:5801 | denotes | hydroxychloroquine |
| T75 | 94-112 | CHEBI:5801 | denotes | hydroxychloroquine |
| T76 | 114-125 | DG_35 | denotes | tocilizumab |
| T77 | 127-136 | DG_29 | denotes | ribavirin |
| T78 | 155-164 | DG_23 | denotes | lopinavir |
| T79 | 165-174 | DG_30 | denotes | ritonavir |
| T80 | 219-224 | SP_6 | denotes | human |
| T81 | 219-224 | NCBITaxon:9606 | denotes | human |
| T82 | 237-241 | G_3 | denotes | ACE2 |
| T83 | 237-241 | PG_10 | denotes | ACE2 |
| T84 | 237-241 | PR:000003622 | denotes | ACE2 |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T16 | 0-266 | Sentence | denotes | Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed. |
| T16 | 0-266 | Sentence | denotes | Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed. |